Navigational Bronchoscopy versus Computed Tomography-guided Transthoracic Needle Biopsy for the Diagnosis of Indeterminate Lung Nodules: protocol and rationale for the VERITAS multicenter randomized trial

Robert J. Lentz; Katherine Frederick-Dyer; Virginia B. Planz; Tatsuki Koyama; Matthew C. Aboudara; Briana Swanner; Lance Roller; See-Wei Low; Cristina Salmon; Sameer K. Avasarala; Todd C. Hoopman; Momen M. Wahidi; Kamran Mahmood; George Z. Cheng; James M. Katsis; Jonathan S. Kurman; Pierre-François D’Haese; Joyce Johnson; Eric L. Grogan; Charla Walston; Lonny Yarmus; Gerard A. Silvestri; Otis B. Rickman; Najib M. Rahman; Fabien Maldonado; the Interventional Pulmonary Outcomes Group (IPOG)

doi:10.1101/2023.11.22.23298915

ABSTRACT

Background Lung nodule incidence is increasing. Many nodules require biopsy to discriminate between benign and malignant etiologies. The gold-standard for minimally invasive biopsy, computed tomography-guided transthoracic needle biopsy (CT-TTNB), has never been directly compared to navigational bronchoscopy, a modality which has recently seen rapid technological innovation and is associated with improving diagnostic yield and lower complication rate. Current estimates of the diagnostic utility of both modalities are based largely on non-comparative data with significant risk for selection, referral, and publication biases.

Methods The VERITAS trial (naVigation Endoscopy to Reach Indeterminate lung nodules versus Transthoracic needle Aspiration, a randomized controlled Study) is a multicenter, 1:1 randomized, parallel-group trial designed to ascertain whether electromagnetic navigational bronchoscopy with integrated digital tomosynthesis is noninferior to CT-TTNB for the diagnosis of peripheral lung nodules 10-30 mm in diameter with pre-test probability of malignancy of at least 10%. The primary endpoint is diagnostic accuracy through 12 months follow-up. Secondary endpoints include diagnostic yield, complication rate, procedure duration, need for additional invasive diagnostic procedures, and radiation exposure.

Discussion The results of this rigorously designed trial will provide high-quality data regarding the management of lung nodules, a common clinical entity which often represents the earliest and most treatable stage of lung cancer. Several design challenges are described. Notably, all nodules are centrally reviewed by an independent interventional pulmonology and radiology adjudication panel relying on pre-specified exclusions to ensure enrolled nodules are amenable to sampling by both modalities while simultaneously protecting against selection bias favoring either modality. Conservative diagnostic yield and accuracy definitions with pre-specified criteria for what non-malignant findings may be considered diagnostic were chosen to avoid inflation of estimates of diagnostic utility.

Trial registration ClinicalTrials.gov NCT04250194

Competing Interest Statement

Fabien Maldonado reports financial support was provided by Medtronic and reports a relationship with Intuitive that includes: consulting or advisory. Otis B. Rickman reports a relationship with Medtronic that includes: consulting or advisory. Lonny Yarmus reports a relationship with Medtronic, Olympus, Intuitive, and Johnson & Johnson that includes: consulting and advisory. Matthew Aboudara reports a relationship with Medtronic that includes: speaking and lecture, and a relationship with Noah Medical that includes: consulting and advisory. Pierre-Francois D'Haese reports a relationship with Upstream Vision LLC that includes: employment and equity/stock ownership.

Clinical Trial

NCT04250194

Funding Statement

This work is supported by an unrestricted research grant from Medtronic (Fridley, Minnesota, USA) and the Pierre Massion Directorship in Pulmonary Medicine (F.M.). E.G reports support from U01 CA152662.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

IRBs of Vanderbilt University Medical Center, UC-San Diego Medical Center, Kootenai Health Hospital (Coeur d'Alene, ID), Rush University Medical Center, Saint Luke's Hospital of Kansas City, Duke University Medical Center, and Medical College of Wisconsin gave ethical approval for this work.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes